Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Travis Clifton

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Annals of Surgical Oncology|August 5, 2020
Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive PatientsPhillip M Kemp Bohan, Derek T Kirby, Robert C Chick, et al.
Annals of Surgical Oncology|March 19, 2017
Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer PatientsG Travis Clifton, Jennifer K Litton, Karen Arrington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
Phase II trial of encapsulated rapamycin to reduce polyp burden associated with familial adenomatous polyposisJoseph C Broderick, Niloy Jewel Samadder, Elena Stoffel, et al.
The Journal of Surgical Research|September 6, 2020
An Educational Intervention Reduces Opioids Prescribed Following General Surgery ProceduresPhillip M Kemp Bohan, Robert C Chick, Morgan E Wall, et al.
Infection Control and Hospital Epidemiology|April 18, 2022
Healthcare worker safety program in a coronavirus disease 2019 (COVID-19) alternate care site: The Javits New York Medical Station experienceChad N Thompson, Christopher Mugford, Joel R Merriman, et al.
Clinical Immunology (Orlando, Fla.)|March 1, 2019
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumorsG Travis Clifton, Kaitlin M Peace, Jarrod P Holmes, et al.
Journal of Surgical Oncology|May 20, 2025
A Validated Ultrasound-Based Scoring System to Stratify Risk of Axillary Metastasis in Breast Cancer: AX-RADS (Axillary Imaging Reporting and Data System)Spencer G Van Decar, Elizabeth L Barbera, Alexandra M Adams, et al.
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.
Familial Cancer|June 9, 2020
Chemoprevention in familial adenomatous polyposis: past, present and futurePhillip M Kemp Bohan, Gautam Mankaney, Timothy J Vreeland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Annals of Surgical Oncology|August 5, 2020
Adjuvant Chemotherapy in Resectable Gallbladder Cancer is Underutilized Despite Benefits in Node-Positive PatientsPhillip M Kemp Bohan, Derek T Kirby, Robert C Chick, et al.
Annals of Surgical Oncology|March 19, 2017
Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer PatientsG Travis Clifton, Jennifer K Litton, Karen Arrington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
Phase II trial of encapsulated rapamycin to reduce polyp burden associated with familial adenomatous polyposisJoseph C Broderick, Niloy Jewel Samadder, Elena Stoffel, et al.
The Journal of Surgical Research|September 6, 2020
An Educational Intervention Reduces Opioids Prescribed Following General Surgery ProceduresPhillip M Kemp Bohan, Robert C Chick, Morgan E Wall, et al.
Infection Control and Hospital Epidemiology|April 18, 2022
Healthcare worker safety program in a coronavirus disease 2019 (COVID-19) alternate care site: The Javits New York Medical Station experienceChad N Thompson, Christopher Mugford, Joel R Merriman, et al.
Clinical Immunology (Orlando, Fla.)|March 1, 2019
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumorsG Travis Clifton, Kaitlin M Peace, Jarrod P Holmes, et al.
Journal of Surgical Oncology|May 20, 2025
A Validated Ultrasound-Based Scoring System to Stratify Risk of Axillary Metastasis in Breast Cancer: AX-RADS (Axillary Imaging Reporting and Data System)Spencer G Van Decar, Elizabeth L Barbera, Alexandra M Adams, et al.
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.
Familial Cancer|June 9, 2020
Chemoprevention in familial adenomatous polyposis: past, present and futurePhillip M Kemp Bohan, Gautam Mankaney, Timothy J Vreeland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.
Pageof 3